Source link : https://www.newshealth.biz/health-news/are-t-dxd-results-in-her2-low-ultralow-breast-cancer-practice-changing/
The antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved progression-free survival (PFS) versus chemotherapy in previously treated metastatic hormone receptor (HR)-positive/HER2-low/ultralow breast cancer, according to a randomized trial presented at the American Society of Clinical Oncology (ASCO) annual meeting. MedPage Today brought together three expert leaders in the field: Moderator Hope S. Rugo, MD, of […]
Author : News Health
Publish date : 2024-06-18 14:00:00
Copyright for syndicated content belongs to the linked Source.
in Health